HNGZY

Hangzhou Tigermed Consulting Co. Ltd

HNGZY, USA

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. In addition, the company offers patient recruitment, investment management, medical registration, pharmaceuticals and regulations consulting, drug safety, bioequivalence, and third-party training services, as well as chemistry, management, and controls services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

https://www.tigermedgrp.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
HNGZY
stock
HNGZY

Tigermed Officially Opens International Headquarters in Hong Kong marketscreener.com

Read more →

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Medium

26.67

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

1.16

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

2.99 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.20 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

22.61 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.19

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Hangzhou Tigermed Consulting Co. Ltd

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.1034

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(9.3)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(5)
Net Net
Possible Net-Net(4)
Quality
High Quality(8)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.